RecruitingPhase 3interventionalRules rewrite

Phase 3: testing Faricimab Injection [Vabysmo] for Polypoidal Choroidal Vasculopathy (PCV)

Q: Is NCT07461441 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07461441?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07461441?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

To measure the how well it works of a personalized treat-and-extend regimen of faricimab for treatment-who have not tried this kind of treatment before polypoidal choroidal vasculopathy

Official registry: https://clinicaltrials.gov/study/NCT07461441 · Yeungnam University College of Medicine · enrollment listed as 50

What this phase means

Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Faricimab Injection [Vabysmo]. The registry lists allocation as na. To measure the how well it works of a personalized treat-and-extend regimen of faricimab for treatment-who have not tried this kind of treatment before polypoidal choroidal vasculopathy

They plan to enroll about 50 people at Daegu. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

Interventions: Faricimab Injection [Vabysmo]

Primary outcome (registry wording): The proportion of patients who reached a treatment interval of ≥16 weeks at Week 96 (LV)

Who it is for (from inclusion criteria)

Ages 50 Years to any
Potential participants are eligible to be included in the study only if all of the following criteria apply:
\[Ocular Conditions\]
BCVA score must be ≤ 78 and ≥ 24 letters at 4 meters starting distance using early treatment diabetic retinopathy study (ETDRS) visual acuity charts at both Screening and Baseline
Greatest liner dimension (GLD) of the total lesion area (branching vascular network \[BVN\] + polypoidal lesion) \< 5400 μm (equivalent to 9 macular photocoagulation study \[MPS\] Disc Area) as delineated by ICGA
\[Systemic Conditions\]
Participants who are able to comply with the study protocol, in the investigator's judgment
For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception (will be defined in details in protocol)

Who the registry excludes

Potential participants are excluded from the study if any of the following criteria apply:
\[Ocular Conditions\] in the Study Eye
Previous treatment with any anti-VEGF drugs or faricimab or investigational drugs at any time prior to Baseline
Previous use of intraocular or periocular steroids within the 6-month period prior to Baseline
Macular laser photocoagulation (focal/grid) or PDT at any time prior to Baseline and peripheral laser photocoagulation within 3 months prior to Baseline
Treatment with investigational therapy (device, drug, or traditional medicine with the exception of vitamins and minerals) within 3 months prior to initiation of study treatment on study Day 1
Presence of subfoveal geographic atrophy or extensive retinal pigment epithelial atrophy involving the central subfield that, in the opinion of the investigator, may limit visual potential

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

1 listed

Yeungnam university medical center — Daegu, Namgu, South Korea (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Cell Collection to Study Eye Diseases

Background: \- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases.

NCT01432847 · Official ClinicalTrials.gov record · National Eye Institute (NEI)

RecruitingNot a traditional drug phaseBethesda, Maryland

National Eye Institute Biorepository for Retinal Diseases

Background: \- To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time.

NCT01496625 · Official ClinicalTrials.gov record · National Eye Institute (NEI)

RecruitingPhase 3Phoenix, Arizona

Phase 3: testing PDS Implant with Ranibizumab 100 mg/mL for Neovascular Age-Related Macular Degeneration

This study will measure the long-term whether it is safe and how hard side effects are to live with of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomly assigned in WR42221.

NCT03683251 · Official ClinicalTrials.gov record · Hoffmann-La Roche

FAQ about this NCT record

Is NCT07461441 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07461441?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07461441?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary